127 related articles for article (PubMed ID: 7804354)
1. Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells.
Smith BW; Kurzman ID; Schultz KT; Czuprynski CJ; MacEwen EG
Cancer Biother; 1993; 8(2):137-44. PubMed ID: 7804354
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo canine mononuclear cell production of tumor necrosis factor induced by muramyl peptides and lipopolysaccharide.
Kurzman ID; Shi F; MacEwen EG
Vet Immunol Immunopathol; 1993 Sep; 38(1-2):45-56. PubMed ID: 8256437
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo production of interleukin-6 induced by muramyl peptides and lipopolysaccharide in normal dogs.
Shi F; Kurzman ID; MacEwen EG
Cancer Biother; 1995; 10(4):317-25. PubMed ID: 8590897
[TBL] [Abstract][Full Text] [Related]
4. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
Fogler WE; Fidler IJ
Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
Kurzman ID; Shi F; Vail DM; MacEwen EG
Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
[TBL] [Abstract][Full Text] [Related]
6. Effect of liposome-muramyl tripeptide combined with recombinant canine granulocyte colony-stimulating factor on canine monocyte activity.
Kurzman ID; Cheng H; MacEwen EG
Cancer Biother; 1994; 9(2):113-21. PubMed ID: 7529085
[TBL] [Abstract][Full Text] [Related]
7. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
Maeda M; Knowles RD; Kleinerman ES
Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
[TBL] [Abstract][Full Text] [Related]
8. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides.
Hoedemakers RM; Vossebeld PJ; Daemen T; Scherphof GL
J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):252-60. PubMed ID: 8334109
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
Shi F; MacEwen EG; Kurzman ID
Cancer Res; 1993 Sep; 53(17):3986-91. PubMed ID: 8358727
[TBL] [Abstract][Full Text] [Related]
10. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
Tandon P; Utsugi T; Sone S
Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
[TBL] [Abstract][Full Text] [Related]
11. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
Kleinerman ES; Maeda M; Jaffe N
Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
[TBL] [Abstract][Full Text] [Related]
12. Activation of human monocytes by free muramyl dipeptide (MDP).
Kildahl-Andersen O; Seim S
Acta Pathol Microbiol Immunol Scand C; 1984 Jun; 92(3):181-7. PubMed ID: 6507104
[TBL] [Abstract][Full Text] [Related]
13. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide.
Phillips NC; Rioux J; Tsao MS
Hepatology; 1988; 8(5):1046-50. PubMed ID: 2971013
[TBL] [Abstract][Full Text] [Related]
14. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
Pahl JH; Kwappenberg KM; Varypataki EM; Santos SJ; Kuijjer ML; Mohamed S; Wijnen JT; van Tol MJ; Cleton-Jansen AM; Egeler RM; Jiskoot W; Lankester AC; Schilham MW
J Exp Clin Cancer Res; 2014 Mar; 33(1):27. PubMed ID: 24612598
[TBL] [Abstract][Full Text] [Related]
15. Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL).
Phillips NC; Moras ML; Chedid L; Petit JF; Tenu JP; Lederer E; Bernard JM; Lefrancier P
J Biol Response Mod; 1985 Oct; 4(5):464-74. PubMed ID: 3935756
[TBL] [Abstract][Full Text] [Related]
16. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
MacEwen EG; Kurzman ID; Rosenthal RC; Smith BW; Manley PA; Roush JK; Howard PE
J Natl Cancer Inst; 1989 Jun; 81(12):935-8. PubMed ID: 2733037
[TBL] [Abstract][Full Text] [Related]
17. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.
Sone S; Mutsuura S; Ogawara M; Tsubura E
J Immunol; 1984 Apr; 132(4):2105-10. PubMed ID: 6699409
[TBL] [Abstract][Full Text] [Related]
18. ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity.
Worth LL; Jia SF; An T; Kleinerman ES
Cancer Immunol Immunother; 1999 Sep; 48(6):312-20. PubMed ID: 10473806
[TBL] [Abstract][Full Text] [Related]
19. [The stimulating action of lipopolysaccharide and muramyl dipeptide on the activation of mononuclear cells in human peripheral blood by recombinant interleukin-2 in vitro].
Rakhmilevich AL; Pelevina MA; Artsimovich NG; Fuks BB
Biull Eksp Biol Med; 1988 Dec; 106(12):698-701. PubMed ID: 3061497
[TBL] [Abstract][Full Text] [Related]
20. Stereo-isomer specific induction of renal cell apoptosis by synthetic muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoglutamine).
Langford MP; Chen D; Welbourne TC; Redens TB; Ganley JP
Mol Cell Biochem; 2002 Jul; 236(1-2):63-73. PubMed ID: 12190122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
